Developer docs
API playgroundTry for free, no card

Search company profiles

Trellus Health

Full company profile

uuid0002mdw

Namestring
Trellus Health
Legal namestring
Trellus Health Inc.
Company typeenum
Public
Founded yearint
2020
Descriptiontext

Trellus Health is a digital health company that develops and commercializes the Trellus Elevate® behavioral intelligence platform, built on the GRITT™ resilience-based methodology originally developed at the Icahn School of Medicine at Mount Sinai's IBD Center and exclusively licensed to the company. The platform measures resilience and behavioral readiness, segments individuals by activation profile, and deploys personalized activation pathways designed to improve therapy initiation, adherence, and persistence in chronic conditions and clinical trials. Two principal modules operate on top of the core platform: Trellus TrialSet™, a clinical trial readiness layer deployed between eligibility confirmation and formal screening to improve randomization rates, and a patient support program layer that integrates into existing PSP/hub ecosystems as a behavioral activation overlay. The initial condition focus is inflammatory bowel disease (Crohn's disease and ulcerative colitis).

The company serves enterprise customers in three primary segments: pharmaceutical companies (clinical trial sponsorship, addressed via the TrialSet vertical and CRO partnerships with ICON plc and PSI Inc.), pharmaceutical companies (patient support programs, addressed via a flagship Johnson & Johnson Health Care Systems contract extended through mid-2026), and health plans and self-insured employers (chronic condition management). Revenue is generated on a B2B subscription basis using fixed monthly management fees, distributed via direct enterprise sales rather than consumer channels. The company operates from a US headquarters in White Plains, NY and a UK office in Cardiff, is publicly listed on AIM, and holds SOC 2 Type 2 certification alongside peer-reviewed clinical validation.

The business is currently in significant financial distress. AIM trading has been suspended since May 8, 2026, the board has engaged restructuring advisors, and management is exploring strategic options including a potential sale of the U.S. operating subsidiary. The company has funded ongoing operations through a series of small, related-party debt facilities from Mount Sinai-affiliated entities and a £5 million convertible loan note facility, in lieu of equity capital. Against this backdrop, customer-facing commercial activity — the J&J extension and TrialSet CRO implementations — has continued but at pilot scale relative to enterprise peer benchmarks.

Short descriptiontext

Trellus Health is a digital health company that operates the Trellus Elevate® behavioral intelligence platform, built on the GRITT™ resilience methodology licensed from Mount Sinai. It serves pharmaceutical companies, CROs, and health plans with behavioral activation tools for IBD chronic care, clinical trial readiness, and patient support programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWhite Plains, United States
HQ citystring
White Plains
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
behavioral health platform, digital chronic care, clinical trial readiness, patient support programs, IBD condition management
Industry1 code
PRIMARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
NAICS code2 codes
  • Computer Systems Design and Related Services54151
  • Computer Systems Design Services541512
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Digital Health Platform
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Trial Services
TypeSubscription Recurring
Description

Trellus TrialSet vertical providing behavioral readiness activation for clinical trial recruitment and retention. Revenue generated through fixed monthly management fees and per-program contracts with pharmaceutical sponsors. Company reports progress with ICON plc for Takeda-sponsored trials and PSI Inc for Sanofi-sponsored late-stage trials.

investing.com
2Patient Support Program Services
TypeSubscription Recurring
Description

Trellus Elevate digital platform provided to healthcare organizations for patient support programs. Extended contract with Johnson & Johnson Health Care Systems through mid-2026 with fixed monthly management fee structure.

in.investing.com
3Digital Chronic Condition Management
TypeSubscription Recurring
Description

Platform-based services for employers and health plans using GRITT™ resilience-based methodology and Trellus Elevate® platform for remote telemedicine care. Initially focused on IBD (Crohn's Disease and ulcerative colitis).

trellushealth.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Trellus Elevate
Description

A behavioral intelligence platform designed to build resilience, strengthen engagement, and improve readiness across treatment and clinical trial journeys for chronic condition management.

trellushealth.com
+1 more record
Core offering1 text field

Trellus Health sells the Trellus Elevate® behavioral intelligence platform, a digital health solution that activates behavioral readiness for therapy success across clinical trials and commercial patient support programs. Built on the GRITT™ resilience-based methodology exclusively licensed from the Icahn School of Medicine at Mount Sinai, the platform is initially focused on inflammatory bowel disease (IBD) and is delivered through a HIPAA-compliant web portal, iOS/Android apps, and enterprise contracts with pharma companies, CROs, and health plans.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Over 85% reduction in unplanned healthcare use
+5 more records
Product overview1 text field

Trellus Health offers Trellus Elevate® — a unified behavioral intelligence platform built on a clinically validated resilience-based methodology developed at Mount Sinai. The platform activates behavioral readiness for therapy success across clinical trials and commercial patient support programs. Key modules include Trellus TrialSet™ for clinical trial recruitment and readiness, and Trellus Elevate® for Patient Support Programs that integrates as a behavioral layer within existing PSP ecosystems. The GRITT™ methodology (exclusively licensed from ISMMS) underpins the platform's approach to chronic condition resilience building. Members access the platform via the Trellus Elevate™ web portal and mobile app (iOS/Android).

Product and service3 records
1Trellus Elevate® Behavioral Intelligence Platform
CategoryDigital Health Platform
Description

A behavioral intelligence platform that activates behavioral readiness for therapy success, improving recruitment, retention, and real-world engagement across clinical trials and patient support programs. Built on a clinically validated, resilience-based methodology, it identifies readiness barriers and strengthens skills needed to sustain participation and persistence. Delivered to enterprise customers in pharma, CRO, health plan, and employer channels.

2Trellus TrialSet™
3Trellus Elevate® for Patient Support Programs
CategoryPatient Support Programs
Description

A behavioral activation layer integrated into patient support program and hub ecosystems that strengthens activation, adherence, and persistence without adding clinical services. Designed to align with pharmaceutical compliance frameworks, it focuses on behavioral and self-management skills throughout the treatment journey for pharmaceutical PSP and hub clients.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Johnson & Johnson Health Care Systems
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-18
Description

Six-month contract extension through mid-2026 to continue providing Trellus Elevate digital platform for inflammatory bowel disease patients. Extension follows successful pilot phase beginning January 2025 with achievement of engagement and satisfaction metrics. Program expanded patient enrollment channels. Same economic terms including fixed monthly management fee.

investing.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

TrialSet vertical implementation for Takeda-sponsored immunology trial. Represents CRO partnership for clinical trial behavioral activation deployment.

3PSI Inc.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

TrialSet implementation for two Sanofi-sponsored late-stage clinical trials. CRO partnership for behavioral readiness activation in late-stage pharmaceutical trials.

investing.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Digital mental health and chronic condition management platform offering therapist-led online programs with employer and health plan distribution. Comparable in digital behavioral health delivery model and health plan/employer GTM.

TypeDirect peer
Description

Developer of prescription digital therapeutics for IBS and other gastrointestinal conditions, with FDA authorization for its Parallel digital therapeutic. Directly comparable to Trellus's regulated, clinically validated behavioral approach for chronic GI conditions.

TypeDirect peer
Description

Prescription digital therapeutics company partnering with pharma to develop software-based treatments across multiple therapeutic areas including chronic conditions. Comparable in clinical rigor, pharma partnership model, and digital therapeutic regulatory pathway.

TypeDirect peer
Description

Decentralized clinical trial technology platform enabling remote patient participation and improving trial recruitment/retention. Overlaps with Trellus TrialSet's clinical trial patient readiness and retention focus.

TypeDirect peer
Description

Patient-centric clinical trial technology platform enabling decentralized trials with eCOA/ePRO and patient engagement tools. Direct competitor in clinical trial patient readiness and digital data collection, intersecting with Trellus TrialSet.

TypeDirect peer
Description

Digital behavioral health platform offering evidence-based mental health and chronic condition management solutions to pharma and payers. Closely comparable to Trellus Elevate's behavioral intelligence and activation framework across chronic conditions.

TypeEmerging player
Description

Decentralized clinical trial platform enabling patient recruitment and remote trial conduct for sponsors. Comparable to Trellus TrialSet in clinical trial patient engagement, though broader across therapeutic areas.

TypeBroad incumbent
Description

Enterprise cloud software provider for life sciences with clinical trial management and patient engagement capabilities. Serves the same pharma customers as Trellus with broader portfolio including CTMS and Vault platforms.

9Bold Health (Bold Care)
TypeDirect peer
Description

Digital therapeutics company focused specifically on gastrointestinal conditions including IBS, offering digital behavioral interventions very similar to Trellus's IBD focus. Direct competitor in the GI behavioral health space with comparable patient-facing digital program model.

TypeEmerging player
Description

Digital therapeutics company focused on behavioral health conditions (insomnia, anxiety) with employer and health plan distribution. Comparable to Trellus Elevate's health plan and employer GTM and behavioral activation methodology, though in mental health rather than GI.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks3 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Trellus Health

Digital Health Platformtrellushealth.com

Trellus Health is a digital health company that operates the Trellus Elevate® behavioral intelligence platform, built on the GRITT™ resilience methodology licensed from Mount Sinai. It serves pharmaceutical companies, CROs, and health plans with behavioral activation tools for IBD chronic care, clinical trial readiness, and patient support programs.

What Trellus Health does

Trellus Health is a digital health company that develops and commercializes the Trellus Elevate® behavioral intelligence platform, built on the GRITT™ resilience-based methodology originally developed at the Icahn School of Medicine at Mount Sinai's IBD Center and exclusively licensed to the company. The platform measures resilience and behavioral readiness, segments individuals by activation profile, and deploys personalized activation pathways designed to improve therapy initiation, adherence, and persistence in chronic conditions and clinical trials. Two principal modules operate on top of the core platform: Trellus TrialSet™, a clinical trial readiness layer deployed between eligibility confirmation and formal screening to improve randomization rates, and a patient support program layer that integrates into existing PSP/hub ecosystems as a behavioral activation overlay. The initial condition focus is inflammatory bowel disease (Crohn's disease and ulcerative colitis).

The company serves enterprise customers in three primary segments: pharmaceutical companies (clinical trial sponsorship, addressed via the TrialSet vertical and CRO partnerships with ICON plc and PSI Inc.), pharmaceutical companies (patient support programs, addressed via a flagship Johnson & Johnson Health Care Systems contract extended through mid-2026), and health plans and self-insured employers (chronic condition management). Revenue is generated on a B2B subscription basis using fixed monthly management fees, distributed via direct enterprise sales rather than consumer channels. The company operates from a US headquarters in White Plains, NY and a UK office in Cardiff, is publicly listed on AIM, and holds SOC 2 Type 2 certification alongside peer-reviewed clinical validation.

The business is currently in significant financial distress. AIM trading has been suspended since May 8, 2026, the board has engaged restructuring advisors, and management is exploring strategic options including a potential sale of the U.S. operating subsidiary. The company has funded ongoing operations through a series of small, related-party debt facilities from Mount Sinai-affiliated entities and a £5 million convertible loan note facility, in lieu of equity capital. Against this backdrop, customer-facing commercial activity — the J&J extension and TrialSet CRO implementations — has continued but at pilot scale relative to enterprise peer benchmarks.

Trellus Health firmographics

Firmographics
Name
Trellus Health
Legal name
Trellus Health Inc.
Website
https://trellushealth.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Trellus Health is a digital health company that operates the Trellus Elevate® behavioral intelligence platform, built on the GRITT™ resilience methodology licensed from Mount Sinai. It serves pharmaceutical companies, CROs, and health plans with behavioral activation tools for IBD chronic care, clinical trial readiness, and patient support programs.
Ownership category
akta.pro rank

Trellus Health industry classification

Industry
Product category
Digital Health Platform
NAICS
Computer Systems Design and Related Services (54151), Computer Systems Design Services (541512)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • Behavioral health platform
  • Digital chronic care
  • Clinical trial readiness
  • Patient support programs
  • IBD condition management

Where Trellus Health is headquartered

Location

Headquarters

HQ city
White Plains
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Trellus Health business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Clinical Trial Services: Trellus TrialSet vertical providing behavioral readiness activation for clinical trial recruitment and retention. Revenue generated through fixed monthly management fees and per-program contracts with pharmaceutical sponsors. Company reports progress with ICON plc for Takeda-sponsored trials and PSI Inc for Sanofi-sponsored late-stage trials.
  2. Patient Support Program Services: Trellus Elevate digital platform provided to healthcare organizations for patient support programs. Extended contract with Johnson & Johnson Health Care Systems through mid-2026 with fixed monthly management fee structure.
  3. Digital Chronic Condition Management: Platform-based services for employers and health plans using GRITT™ resilience-based methodology and Trellus Elevate® platform for remote telemedicine care. Initially focused on IBD (Crohn's Disease and ulcerative colitis).

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Trellus Health product offering

Product offering

Core offering

Trellus Health sells the Trellus Elevate® behavioral intelligence platform, a digital health solution that activates behavioral readiness for therapy success across clinical trials and commercial patient support programs. Built on the GRITT™ resilience-based methodology exclusively licensed from the Icahn School of Medicine at Mount Sinai, the platform is initially focused on inflammatory bowel disease (IBD) and is delivered through a HIPAA-compliant web portal, iOS/Android apps, and enterprise contracts with pharma companies, CROs, and health plans.

Product overview

Trellus Health offers Trellus Elevate® — a unified behavioral intelligence platform built on a clinically validated resilience-based methodology developed at Mount Sinai. The platform activates behavioral readiness for therapy success across clinical trials and commercial patient support programs. Key modules include Trellus TrialSet™ for clinical trial recruitment and readiness, and Trellus Elevate® for Patient Support Programs that integrates as a behavioral layer within existing PSP ecosystems. The GRITT™ methodology (exclusively licensed from ISMMS) underpins the platform's approach to chronic condition resilience building. Members access the platform via the Trellus Elevate™ web portal and mobile app (iOS/Android).

Differentiator

Problem solved

Functional benefit

Brands

  • Trellus Elevate: A behavioral intelligence platform designed to build resilience, strengthen engagement, and improve readiness across treatment and clinical trial journeys for chronic condition management.
  • Trellus TrialSet

Products and services

  • Trellus Elevate® Behavioral Intelligence Platform A behavioral intelligence platform that activates behavioral readiness for therapy success, improving recruitment, retention, and real-world engagement across clinical trials and patient support programs. Built on a clinically validated, resilience-based methodology, it identifies readiness barriers and strengthens skills needed to sustain participation and persistence. Delivered to enterprise customers in pharma, CRO, health plan, and employer channels.
  • Trellus TrialSet™
  • Trellus Elevate® for Patient Support Programs A behavioral activation layer integrated into patient support program and hub ecosystems that strengthens activation, adherence, and persistence without adding clinical services. Designed to align with pharmaceutical compliance frameworks, it focuses on behavioral and self-management skills throughout the treatment journey for pharmaceutical PSP and hub clients.

Quantifiable outcome

  • Over 85% reduction in unplanned healthcare use
  • +5 more outcomes

Companies that use Trellus Health

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Trellus Health technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Trellus Health partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • Johnson & Johnson Health Care SystemsflagshipStrategic or Co-development Partner · 18 February 2026Six-month contract extension through mid-2026 to continue providing Trellus Elevate digital platform for inflammatory bowel disease patients. Extension follows successful pilot phase beginning January 2025 with achievement of engagement and satisfaction metrics. Program expanded patient enrollment channels. Same economic terms including fixed monthly management fee.
  • ICON plccoreStrategic or Co-development PartnerTrialSet vertical implementation for Takeda-sponsored immunology trial. Represents CRO partnership for clinical trial behavioral activation deployment.
  • PSI Inc.coreStrategic or Co-development PartnerTrialSet implementation for two Sanofi-sponsored late-stage clinical trials. CRO partnership for behavioral readiness activation in late-stage pharmaceutical trials.

Scale indicators10 records

Recent moves6 records

Expansion highlights4 records

Trellus Health competitors and assessment

Company assessment

Emerging players

  • Meru Health: Digital mental health and chronic condition management platform offering therapist-led online programs with employer and health plan distribution. Comparable in digital behavioral health delivery model and health plan/employer GTM.
  • Curebase: Decentralized clinical trial platform enabling patient recruitment and remote trial conduct for sponsors. Comparable to Trellus TrialSet in clinical trial patient engagement, though broader across therapeutic areas.
  • Big Health: Digital therapeutics company focused on behavioral health conditions (insomnia, anxiety) with employer and health plan distribution. Comparable to Trellus Elevate's health plan and employer GTM and behavioral activation methodology, though in mental health rather than GI.

Direct peers

  • Mahana Therapeutics: Developer of prescription digital therapeutics for IBS and other gastrointestinal conditions, with FDA authorization for its Parallel digital therapeutic. Directly comparable to Trellus's regulated, clinically validated behavioral approach for chronic GI conditions.
  • Click Therapeutics: Prescription digital therapeutics company partnering with pharma to develop software-based treatments across multiple therapeutic areas including chronic conditions. Comparable in clinical rigor, pharma partnership model, and digital therapeutic regulatory pathway.
  • Science 37: Decentralized clinical trial technology platform enabling remote patient participation and improving trial recruitment/retention. Overlaps with Trellus TrialSet's clinical trial patient readiness and retention focus.
  • Medable: Patient-centric clinical trial technology platform enabling decentralized trials with eCOA/ePRO and patient engagement tools. Direct competitor in clinical trial patient readiness and digital data collection, intersecting with Trellus TrialSet.
  • Happify Health: Digital behavioral health platform offering evidence-based mental health and chronic condition management solutions to pharma and payers. Closely comparable to Trellus Elevate's behavioral intelligence and activation framework across chronic conditions.
  • Bold Health (Bold Care): Digital therapeutics company focused specifically on gastrointestinal conditions including IBS, offering digital behavioral interventions very similar to Trellus's IBD focus. Direct competitor in the GI behavioral health space with comparable patient-facing digital program model.

Broad incumbents

  • Veeva Systems: Enterprise cloud software provider for life sciences with clinical trial management and patient engagement capabilities. Serves the same pharma customers as Trellus with broader portfolio including CTMS and Vault platforms.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks3 records

Key highlights7 records

Customer concentration

Trellus Health social profiles

Digital presence

Trellus Health compliance and trust

Trust signal

Compliance1 record

Trellus Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Trellus Health leadership team

Management profile

Number of profiles

Profiles10 records

Trellus Health subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Trellus Health funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Trellus Health M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trellus Health

What does Trellus Health do?

Trellus Health sells the Trellus Elevate® behavioral intelligence platform, a digital health solution that activates behavioral readiness for therapy success across clinical trials and commercial patient support programs. Built on the GRITT™ resilience-based methodology exclusively licensed from the Icahn School of Medicine at Mount Sinai, the platform is initially focused on inflammatory bowel disease (IBD) and is delivered through a HIPAA-compliant web portal, iOS/Android apps, and enterprise contracts with pharma companies, CROs, and health plans.

Is Trellus Health a public or private company?

Trellus Health is a public company. It is classified as public and is currently operating.

When was Trellus Health founded?

Trellus Health was founded in 2020. It employs 11 to 50 people.

Where is Trellus Health based?

Trellus Health is headquartered in White Plains, United States, in the North America region.

How does Trellus Health make money?

Three revenue lines are on record. Clinical Trial Services are the primary driver. The others are patient Support Program Services and digital Chronic Condition Management.

Who are Trellus Health's main competitors?

Emerging players on record are Meru Health, Curebase and Big Health. Direct peers are Mahana Therapeutics, Click Therapeutics, Science 37, Medable, Happify Health and Bold Health (Bold Care). Veeva Systems is listed as a broad incumbent.

Does Trellus Health have an API?

No public API is recorded for Trellus Health.

What industry is Trellus Health in?

Trellus Health's product category is Digital Health Platform. Its primary akta.pro industry code is HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection. Its NAICS code is 54151 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InvestegateAIM Rule 17 DisclosureRenalytix plc issued an AIM Rule 17 disclosure on 24 August 2026 stating that Non-Executive Director Erik Lium was a Non-Executive Director of Trellus Health plc within 12 months of its administration. The announcement says the disclosure is a regulatory requirement and does not affect the company's financial performance or operational status.BusinessCloudHealthTech Trellus to crash into administrationHealthTech company Trellus Health plc has announced its intention to enter administration after failing to secure new funding and running out of cash. The board appointed administrators from Quantuma Advisory Ltd to protect creditors' interests while seeking a buyer for the company's assets, including its US subsidiary. This move follows suspended trading and previous cost-saving measures that were insufficient to keep the business viable.Investing.comTrellus Health files notice to appoint administrators By Investing.comTrellus Health plc filed a notice to appoint administrators from Quantuma Advisory Ltd due to insufficient funds to continue trading as a going concern. The company, whose shares have been suspended since May 2026, is working with restructuring advisers to sell assets while warning that shareholders are not expected to receive any returns.Investing.comTrellus Health files notice to appoint administrators By Investing.comTrellus Health plc has filed a notice to appoint administrators from Quantuma Advisory Ltd due to insufficient funds to continue trading. The company's board aims to complete the appointment within five business days while seeking a buyer for certain assets, including its U.S. subsidiary Trellus Health Inc. The board warned that shareholders are not expected to receive any returns from a potential sale.MarketScreenerTrellus Health's US Subsidiary Gets Loan from Executive ManagementTrellus Health's US subsidiary, Trellus Health Inc., secured a loan from its executive management. The funding is part of Trellus Health's ongoing focus on providing healthcare solutions for chronic conditions, particularly inflammatory bowel disease (IBD).InvestegateLoan and Related Party TransactionTrellus Health plc's US subsidiary secured a $50,000 unsecured loan from executive management, with CEO Dr. Marla Dubinsky participating for $20,000. The loan carries 5% annual interest and is repayable by September 24, 2026, or upon a related transaction, extending cash runway to late August 2026. Discussions with a prospective purchaser have been discontinued, with earlier-stage talks ongoing.Investing.comTrellus Health secures $260,000 loan from Mount Sinai By Investing.comTrellus Health plc announced that its subsidiary Trellus Health Inc. has entered into a $260,000 unsecured loan agreement with Mount Sinai Health System, extending the company's cash runway until July 31, 2026. The loan accrues interest at 8% annually starting December 19, 2026, and is due for repayment on June 19, 2027, or 90 days following the sale of the subsidiary. The company's shares have been suspended from trading on AIM since May 8, 2026, and its board has engaged restructuring advisors while exploring strategic options including a potential sale of the U.S. subsidiary.Investing.comTrellus Health secures $260,000 loan from Mount Sinai By Investing.comTrellus Health Inc., a wholly-owned subsidiary of Trellus Health plc, has entered into a $260,000 unsecured loan agreement with Mount Sinai Health System to extend cash runway until July 31, 2026. The loan carries an 8% annual interest rate starting December 19, 2026, and is due for repayment on June 19, 2027, or 90 days following the completion of a sale of the subsidiary. The company's shares have been suspended from trading on AIM since May 8, 2026, and the board has engaged restructuring advisors while exploring strategic options including a potential sale of the U.S. subsidiary.BusinessCloudTrellus shares suspended as cash set to run outTrellus Health suspended AIM trading after failing to secure new funding, with cash runway extending to mid-June 2026 via cost cuts and a co-founder loan. The board is evaluating options including selling its US subsidiary.UK Investor MagazineAIM movers: Mothercare suffering and Trellus Health renews Pfizer licenceThis article provides a market update on several AIM-listed companies, highlighting significant share price movements driven by corporate developments. Key events include Trellus Health renewing a licensing agreement with Pfizer and SysGroup reporting improved full-year revenues due to the acquisition of Saxis.